The minipig as a programmable translational platform for experimental oncofertility
4 affiliations
- 1Cancer Biotechnology Laboratory, Center for Technological Development, Federal University of Pelotas
- 2INCT Bio : Translational Biodiscovery and Biomodels/CNPq
- 3Human Genome and Stem Cell Research Center, Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo
- 4Department of Pathology, School of Veterinary Medicine and Animal Science, University of São Paulo
Abstract
Experimental oncofertility remains fragmented across models of cancer biology, treatment-associated gonadotoxicity, fertility preservation, and reproductive recovery. We propose extending the Oncopig concept into a translational platform that reconnects these states within one genetically defined, cancer-bearing host. The Oncopig provides the oncologic backbone, combining programmable cancer in an immunocompetent large-animal host with clinically scaled intervention and longitudinal sampling. High-resolution porcine genomics, CRISPR-based genome engineering, somatic-cell nuclear transfer for line generation, comparative experimental pathology, and mature reproductive biotechnology extend this architecture toward reproductive endpoints. Here, programmability refers to deliberate specification of the cancer state—genotype, cell lineage or induction strategy, and timing—whereas the reproductive phenotype is measured longitudinally rather than programmed. Distant-cancer modules can test whether cancer status modifies gonadotoxicity, while reproductive-organ modules require disease-specific alleles, appropriate cell-of-origin targeting, and pathology-led validation. Because porcine and human reproduction align in several endocrine and gonadal processes but differ in cycle organization, implantation, placentation, and pregnancy, translation should emphasize process-level endpoints rather than numerical equivalence. The platform is particularly suited to unresolved questions involving targeted therapies and immunotherapies, preservation timing, and pediatric or prepubertal patients. Porcine reproductive biotechnology provides functional endpoints from gonadal tissue and gametes to embryos and offspring. Rather than replacing rodent or human-based models, the Oncopig framework adds an integrated translational layer for questions requiring clinically scaled intervention, longitudinal physiology, and functional reproductive recovery.
Related
- Transcriptomic profiling of tropomyosin isoforms in bladder cancer: multi-platform sequencing and experimental validation
- Allogeneic CAR-T, CAR-NK, and in vivo CAR-T for immune-mediated inflammatory diseases: comparative evidence, platform trade-offs, and translational challenges
- Volatile Anesthetic-Based Combination Strategies Against Ischemia–Reperfusion Injury: Experimental Evidence, Molecular Mechanisms, and Translational Limitations
- Development and qualification of recombinant Göttingen Minipig CYP3A22 and CYP3A29
- The progestin anchor: salvaging mature oocyte yield after an unplanned six-day gonadotropin pause in oncofertility-a case report.
BibTeX
@article{wedy2026minipig,
title = {{The minipig as a programmable translational platform for experimental oncofertility}},
author = {Rodrigo Albertho Almeida Wedy and Lucas Damé Simões and Bruna Silveira Pacheco and Priscila Marques Moura de Leon and Fabiana Kömmling Seixas and Ligiane Leme and Luciano Abreu Brito and Ernesto Goulart and Maria Lucia Zaidan Dagli and Tiago Veiras Collares},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1981709},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1981709/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The minipig as a programmable translational platform for experimental oncofertility
AU - Rodrigo Albertho Almeida Wedy
AU - Lucas Damé Simões
AU - Bruna Silveira Pacheco
AU - Priscila Marques Moura de Leon
AU - Fabiana Kömmling Seixas
AU - Ligiane Leme
AU - Luciano Abreu Brito
AU - Ernesto Goulart
AU - Maria Lucia Zaidan Dagli
AU - Tiago Veiras Collares
PY - 2026
DA - 2026/10/15
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1981709
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1981709/full
AB - Experimental oncofertility remains fragmented across models of cancer biology, treatment-associated gonadotoxicity, fertility preservation, and reproductive recovery. We propose extending the Oncopig concept into a translational platform that reconnects these states within one genetically defined, cancer-bearing host. The Oncopig provides the oncologic backbone, combining programmable cancer in an immunocompetent large-animal host with clinically scaled intervention and longitudinal sampling. High-resolution porcine genomics, CRISPR-based genome engineering, somatic-cell nuclear transfer for line generation, comparative experimental pathology, and mature reproductive biotechnology extend this architecture toward reproductive endpoints. Here, programmability refers to deliberate specification of the cancer state—genotype, cell lineage or induction strategy, and timing—whereas the reproductive phenotype is measured longitudinally rather than programmed. Distant-cancer modules can test whether cancer status modifies gonadotoxicity, while reproductive-organ modules require disease-specific alleles, appropriate cell-of-origin targeting, and pathology-led validation. Because porcine and human reproduction align in several endocrine and gonadal processes but differ in cycle organization, implantation, placentation, and pregnancy, translation should emphasize process-level endpoints rather than numerical equivalence. The platform is particularly suited to unresolved questions involving targeted therapies and immunotherapies, preservation timing, and pediatric or prepubertal patients. Porcine reproductive biotechnology provides functional endpoints from gonadal tissue and gametes to embryos and offspring. Rather than replacing rodent or human-based models, the Oncopig framework adds an integrated translational layer for questions requiring clinically scaled intervention, longitudinal physiology, and functional reproductive recovery.
SN - 2234-943X
ER -